ng28ÄϹ¬½«ÔÚ2023 ESMO´ó»áÉÏչʾÖ×Áö²úÆ·ÏߺÍÏà¹ØÑо¿½øÕ¹Çé¿ö

ng28ÄϹ¬Öêʽ»áÉçÐû²¼£¬½«ÔÚ10ÔÂ20ÈÕÖÁ24ÈÕÓÚÎ÷°àÑÀÂíµÂÀï¾ÙÐеÄÅ·ÖÞÖ×ÁöÄÚ¿Æѧ»á£¨ESMO£©2023 Äê´ó»áÆڼ䣬½éÉÜÆäÖ×Áö²úÆ·ÏߺÍÏà¹ØÑо¿½øÕ¹Çé¿ö¡£

¾«²ÊÄÚÈÝ°üÀ¨£ºÒªº¦ÐÔIIIÆÚCLEAR£¨Ñо¿307£©/KEYNOTE-581ÊÔÑéתÒƵĻùÏßÌØÕ÷¶ÔÖ×Áö·´Ó¦½øÐеÄʺóÆÊÎö£¬¸ÃÊÔÑéÆÀ¹ÀÁËng28ÄϹ¬Ñз¢µÄ¿Ú·þ¶à°ÐµãÀÒ°±ËἤøÊÜÌåÒÖÖƼÁÀÖÎÀÂê?£¨ÂØ·¥ÌæÄᣩÁªºÏMSDµÄ¿¹PD-1ÁÆ·¨¿ÉÈð´ï?£¨ÅÁ²©ÀûÖéµ¥¿¹£©ÓëÊæÄáÌæÄáÓÃÓÚÍíÆÚÉöϸ°û°©»¼ÕßÒ»ÏßÖÎÁƵÄÇé¿ö£¨NCT02811861£»ÑÝʾÎĸ壺#1903P£©¡£±ðµÄ£¬»¹½«½éÉÜÒªº¦ÐÔ IIIÆÚÑо¿ 309/KEYNOTE-775 ÊÔÑé¶ÔÍê³ÉÅÁ²©ÀûÖéµ¥¿¹ÖÎÁƲ¢¼ÌÐø½ÓÊÜÂØ·¥ÌæÄáÖÎÁƵÄÍíÆÚ×Ó¹¬ÄÚĤ°©»¼ÕßµÄÁÆЧ½øÐеÄ̽Ë÷ÐÔÆÊÎö£¨NCT03517449£»Ñݽ²£º#748P£©¡£

ng28ÄϹ¬Ê×ϯ¿Æѧ¹Ù¼æ¸ß¼¶¸±×ܲÃTakashi Owa²©Ê¿ÌåÏÖ£¬¡°×÷Ϊһ¼ÒÒÔ¡±hhc¡±£¨human health care, ÌåÌùÈËÀཡ¿µ£©ÀíÄîΪÇý¶¯Á¦µÄÑз¢Ð͹«Ë¾£¬ÎÒÃÇÖÂÁ¦ÓÚͨ¹ýÎÒÃÇÇ¿´óµÄ²úÆ·×éºÏºÍ¹ÜÏßÀ´Íƶ¯°©Ö¢Ò©Îï¿ÆѧµÄÉú³¤£¬´Ó¶ø¸ÄÉÆ»¼Õß¼°Æä¼ÒÊôµÄÉú»î¡£ÔÚ½ñÄêµÄESMO¼¯»áÉÏ£¬À´×ÔÒªº¦ÐÔIIIÆÚCLEARÊÔÑéºÍ309/KEYNOTE-775ÊÔÑéµÄÆÊÎö½á¹û£¬¿ÉÄÜ»áΪÍíÆÚÉöϸ°û°©ºÍijЩÀàÐ͵ÄÍíÆÚ×Ó¹¬ÄÚĤ°©»¼ÕßµÄÖÎÁÆÌṩ¸üÉîÈëµÄÁ˽⡣ÎÒÃÇÒ²ÆÚ´ý×Å·ÖÏíÂØ·¥ÌæÄáºÍÑз¢Êý¾Ý£¬²¢ÓëÉç»á¸÷½ç½øÐÐÖØÒªµÄ¿Æѧ½»Á÷£¬ÅäºÏÍƶ¯Ö×ÁöÑо¿ÏòÇ°Éú³¤¡£¡±

LEAP (LEnvatinib And Pembrolizumab)ÁÙ´²ÏîÄ¿½«Ðû²¼ÆäËüÊý¾Ý£¬°üÀ¨LEAP-014ÈýÆÚÊÔÑéµÄÄþ¾²ÐÔÊÔÑé½á¹û£¬¸ÃÊÔÑéÆÀ¹ÀÁËÂØ·¥ÌæÄáÁªºÏÅÁ²©ÀûÖéµ¥¿¹ºÍ»¯ÁÆ×÷Ϊʳ¹ÜÁÛ°©»¼ÕßµÄÖÎÁƼƻ®Ñ¡ÏNCT04949256£»Ñݽ²£º#1534P£©¡£ÂØ·¥ÌæÄáÓëÖ÷Òª±ÈÕÕÒ©Îï×÷Ϊ²»¿ÉÇгý¸Îϸ°û°©»¼ÕßÒ»ÏßÖÎÁƼƻ®µÄÍøÂçÜöÝÍÆÊÎöÒ²½«ÔÚ¼¯»áº£±¨ÉÏչʾ£¨Ñݽ²£º#1007P£©¡£

ÆäËüÑо¿½á¹ûÒ²½«ÔÚº£±¨ÉÏչʾ£¬È磺ÆÀ¹À°¬Á¢²¼ÁÖµÄÖ¬ÖÊÌåÖƼÁE7389-LF×÷ΪתÒÆÐÔ/ÍíÆÚHER2ÒõÐÔÈéÏÙ°©»¼ÕßDZÔÚÒ»Ïß»¯ÁÆÑ¡ÔñµÄIÆÚÑо¿¼ÁÁ¿À©Õ¹²¿·ÖµÄ½á¹û£¨Ñݽ²£º#405P£©¡£±ðµÄ£¬»¹½«½éÉÜfarletuzumab ecteribulin£¨FZEC£¬Ô­ÃûMORAb-202£©µÄÁÙ´²Ç°Ñо¿·ÖÏí£¬ÕâÊÇÒ»ÖÖÒ¶ËáÊÜÌå¦Á£¨FR¦Á£©°ÐÏò¿¹Ìå-Ò©ÎïżÁªÎADC£©£¬ÓÃÓÚ×Ó¹¬ÄÚĤ°©Ö¢£¨Õ¹Ê¾£º#786P£©¡£

±¾ÐÂΟåÌÖÂÛÁËÑо¿ÐÔ»¯ºÏÎïºÍFDAÒÑÅú×¼²úÆ·µÄÑо¿ÐÔÓÃ;¡£²¢·Çת´ï¹ØÓÚÁÆЧºÍÄþ¾²ÐԵĽáÂÛ£¬²»°ü¹ÜÈκÎÑо¿ÐÔ»¯ºÏÎï»òFDAÒÑÅú×¼²úÆ·µÄÑо¿ÐÔÓÃ;½«ÀÖ³ÉÍê³ÉÁÙ´²¿ª·¢»ò»ñµÃFDAÅú×¼¡£

ÍêÕûÇåµ¥ÈçÏ£¬ÕâЩժҪ½«ÓÚ½«ÓÚ2023Äê10ÔÂ16ÈÕÐÇÆÚÒ»ÉÏÎç12:05ͨ¹ýESMOÍøÕ¾Ìṩ¡£

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

?

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120